AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arcutis Biotherapeutics I... (ARQT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.46

0.47 (3.62%)

At close: Feb 20, 2025, 3:59 PM

13.65

1.41%

After-hours: Feb 20, 2025, 06:18 PM EST

undefined% (undefined)

Bid	13.43
Market Cap	1.58B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.67
PE Ratio (ttm)	-8.06
Forward PE	n/a
Analyst	Buy

Ask	13.65
Volume	1,384,703
Avg. Volume (20D)	2,128,686
Open	12.96
Previous Close	12.99
Day's Range	12.87 - 13.72
52-Week Range	6.99 - 16.20
Beta	undefined

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 31, 2020

Employees 296

Stock Exchange NASDAQ

Ticker Symbol ARQT

Website https://www.arcutis.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 41.16% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arcutis Biotherapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+7.14%

Arcutis Biotherapeutics shares are trading higher ... Unlock content with Pro Subscription

9 months ago

+13.65%

Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

News

3 days ago · zacks.com

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

1 week ago · zacks.com

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ne...

1 week ago · zacks.com

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Arcutis Biotherapeutics (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem...

1 month ago · zacks.com

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade

The consensus price target hints at a 37.4% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

1 month ago · zacks.com

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

1 month ago · zacks.com

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

2 months ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT's 50-day simple moving average broke out a...

2 months ago · zacks.com

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

3 months ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggest...

3 months ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, an...